RxDoctor Payments DataLook up a doctor →

Juan Pulido, MD

Pulmonary Disease · Jacksonville Beach, FLNPI 1336293620

Payments from drug & device makers

$588,097in general payments, 2019–2025

Across 341 payments — averaging $1724.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$368K
  • Actelion Pharmaceuticals US, Inc.$111K
  • Medtronic$55K
  • AstraZeneca$29K
  • Fisher & Paykel Healthcare Inc$15K
  • Actelion Pharmaceuticals, Ltd$6K
  • plus $5K from 23 others

What the payments were for

  • Speaking & faculty fees$92,47771%
  • Travel & lodging$27,62321%
  • Food & beverage$9,9178%
  • Education$1640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$588,097 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$346,571
Medicare patients
555
Services billed
3,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan25$317,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$151,580
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,043
Spiriva RespimatTiotropium Bromide17$10,909
Tadalafil17$6,777
Albuterol Sulfate HfaAlbuterol Sulfate58$1,129
Montelukast Sodium26$426
Famotidine12$234
Pantoprazole Sodium13$112
Methylprednisolone11$63
Prednisone16$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$110,822$317,04925 claims
GSKTrelegy Ellipta$216$151,580133 claims
AstraZenecaBreztri Aerosphere$28,509$14,04317 claims
Boehringer IngelheimSpiriva Respimat$300$10,90917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →